Kamau Therapeutics, a gene-editing startup emerging from relative quiet since 2023, disclosed first clinical data from its revamped sickle cell program, setting out early signals ahead of upcoming conference coverage. The updates center on its approach to correcting the sickle mutation in β-globin—aimed at restoring adult hemoglobin expression in gene-edited hematopoietic stem cells. The company’s disclosures are positioned to inform discussions with regulators on next-step registration trial design, with early cohorts reported as transfusion-independent and without pain crises since infusion.